Access
Login/Register
Supplier Login
Bioiberica, a global life science company, proudly announces the launch of its native (undenatured) type II collagen ingredient for joint health, Collavant® n2, to the Japanese nutraceuticals market, made possible through a strategic partnership with local distributor Ryusendo Co., Ltd. Under the new agreement Collavant® n2 will become Bioiberica’s first branded nutraceutical ingredient to be launched in Japan, building on more than 20 years of success in the region achieved through the company’s industry-leading pharmaceutical ingredients. Effective at only 40 mg/day, Collavant® n2 works through a mechanism of action called oral tolerance, turning off the body’s immune response against endogenous type II collagen to support cartilage health. The launch in the tightly regulated Japanese supplement market reflects Bioiberica’s status as a trusted global supplier of high-quality, scientifically-validated health and wellness ingredients.
A major milestone for Bioiberica and the Japanese joint health segment
The new agreement with Ryusendo and launch of Collavant® n2 marks Bioiberica’s first entry into the Japanese nutraceuticals space, a dynamic and fast-growing market with a healthy 6.35% CAGR predicted between 2026 and 2034.[1] The joint health segment in the country is poised for further rapid expansion, fuelled by an aging population and a growing interest in preventative mobility support.[2],[3] While the market is ripe for innovation, the strict safety, quality and efficacy standards upheld by the Japanese Ministry for Health, Labour and Welfare (MHLW) and Consumer Affairs Agency (CAA) make the Japanese wellness arena notoriously challenging to enter, even for brands that are well-established in other parts of the world.[4]
The fact that Collavant® n2 complies with all relevant Japanese food regulations and is therefore approved for sale in Japan, validates the ingredient’s status as a trusted source of native (undenatured) type II collagen, supported by seven scientific studies. In a recently published clinical trial supplementation with 40 mg/day of Collavant® n2 was shown to correlate with a significant decrease in cross-linked C-terminal telopeptide of type II collagen (CTX-II), a byproduct of collagen destruction considered one of the most validated biomarkers of cartilage degradation. These results suggest that taking Collavant® n2 could help to protect articular cartilage in healthy individuals experiencing joint discomfort during physical activity.[5]
(Photo source: Bioiberica)
The launch of this ingredient in Japan gives local dietary supplement and functional food manufacturers a valuable opportunity to differentiate with a European-produced, science-backed ingredient with demonstrable benefits for healthy consumers looking to support an active lifestyle.
Building strong relationships in one of Asia’s leading markets
Establishing a foothold in Japan's health and nutrition sector not only required Bioiberica to demonstrate the scientific and regulatory credentials of Collavant® n2, but also the long-term trust and sustained reliability that define Japanese business partnerships.
As Yoshiaki Shiojima, President & CEO, Ryusendo Co., Ltd. commented, "The decision to partner with Bioiberica was based on our confidence in the company’s commitment to quality, scientific rigour and transparency. As a trusted and experienced operator in Japan's nutraceutical market, Ryusendo brings the market knowledge and industry relationships necessary to position Collavant® n2 for success with local dietary supplement brands. We look forward to a productive partnership with Bioiberica based on a shared vision to support long-term health and wellbeing. We will also leverage Ryusendo’s accumulated experience in clinical research, Foods with Function Claims (FFC) notification support, and scientific communication in Japan to further enhance the value of Collavant® n2 in the Japanese market.
Antonio Vendrell, Marketing & Communications Director at Bioiberica added, "Our new partnership with Ryusendo marks a significant milestone in Bioiberica's ongoing mission to bring science-backed, sustainably produced ingredients to health-conscious consumers around the world, and points to our broader growth ambitions across the APAC market.” He continues, “Bioiberica’s established reputation for circular, fully traceable production has also played an important role in bringing Collavant® n2 to Japan. Meeting the country's stringent import and quality regulations requires complete transparency across the supply chain, an area where Bioiberica's processes are well-placed to deliver. Looking ahead, we see this agreement as the key that unlocks limitless opportunities in one of the world’s most dynamic and innovative nutraceutical markets.”
--
[1] https://www.imarcgroup.com/japan-nutraceuticals-market
[2] https://www.grandviewresearch.com/horizon/outlook/bone-and-joint-health-supplements-market/japan
[3] https://www.lucintel.com/joint-supplement-market-in-japan.aspx
[4] Blaze J. A Comparison of Current Regulatory Frameworks for Nutraceuticals in Australia, Canada, Japan, and the United States. Innov Pharm. 2021 Apr 21;12(2):10.24926/iip.v12i2.3694. doi: 10.24926/iip.v12i2.3694. PMID: 34345505; PMCID: PMC8326690.
[5] Möller et al. Efficacy and tolerability of native (undenatured) type II collagen supplementation for joint health in healthy volunteers: a randomized double-blind placebo-controlled study. Nutr J. 2026 Mar 6;25(1):46.